CJC-1295 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 is Not FDA-approved. Research chemical status. Banned by WADA. Regulations vary by country, and the legal landscape for peptides is evolving. This guide covers the current legal status and what researchers need to know.
Is CJC-1295 Legal?
Not FDA-approved. Research chemical status. Banned by WADA.
The legal landscape for peptides like CJC-1295 is nuanced and varies by jurisdiction. This guide covers the current regulatory status and what researchers need to know.
What Is the Legal Status of CJC-1295 in the United States?
CJC-1295 is generally available as a research chemical in the US. It is not FDA-approved for human use, which means it cannot be marketed, sold, or prescribed as a drug or supplement.
However, research chemicals can be legally purchased for laboratory, in vitro, or educational use. The key legal distinction is between personal research use and human consumption — the latter is not approved.
Is CJC-1295 Legal Internationally?
Peptide regulations vary significantly by country. Some jurisdictions classify peptides as prescription-only compounds, while others allow research chemical sales similar to the US.
Australia: Most peptides require a prescription. UK: Generally available for research. Canada: Research chemical status. EU: Varies by country. Always check local regulations before purchasing.
Is CJC-1295 Banned in Sports?
WADA (World Anti-Doping Agency) has banned CJC-1295 in athletic competition.
If you compete in any organized sport, assume all peptides are prohibited unless you have confirmed otherwise with your sport's governing body.
How Is the Legal Landscape Changing?
Peptide regulation is an evolving area. The FDA has increased scrutiny of compounding pharmacies and research chemical vendors in recent years. Some peptides that were freely available have faced new restrictions.
Staying informed about regulatory changes is important for researchers working with CJC-1295 and similar compounds.
Bottom Line on CJC-1295 Legality
Not FDA-approved. Research chemical status. Banned by WADA. Researchers should ensure compliance with their local laws and use CJC-1295 only for legitimate research purposes.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 Dosage Guide
- CJC-1295 Benefits
- CJC-1295 Side Effects
- CJC-1295 Stacking Guide
- CJC-1295 Cycle Guide
- CJC-1295 Research
Calculate Your CJC-1295 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
What is the recommended CJC-1295 dosage?
Common dosages: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Cycle length: 8-12 weeks, often paired with Ipamorelin. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
Is CJC-1295 safe?
CJC-1295 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical status. Banned by WADA. All research should follow appropriate safety protocols.